{
    "clinical_study": {
        "@rank": "134770", 
        "brief_summary": {
            "textblock": "RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer.\n\n      PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who\n      have low blood counts caused by hematologic cancer."
        }, 
        "brief_title": "Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer", 
        "condition": [
            "Anemia", 
            "Leukemia", 
            "Neutropenia", 
            "Thrombocytopenia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Neutropenia", 
                "Thrombocytopenia", 
                "Leukemia, Large Granular Lymphocytic"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the frequency of cytopenic response in patients with T-cell large granular\n           lymphocytic leukemia treated with cyclosporine.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of\n      disease progression or unacceptable toxicity.\n\n      Patients are followed every 4 months for 1 year and then every 6 months for 9 years.\n\n      PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of T-cell large granular lymphocytic leukemia\n\n               -  Increased numbers of large granular lymphocytes in peripheral blood smears\n\n               -  CD3+CD8+CD57+ immunophenotype by flow cytometry AND\n\n               -  CD3+CD57+ cell count at least 2,000/mm^3 OR\n\n               -  CD3+CD57+ cell count at least 500/mm^3 with clonal T-cell receptor beta gene\n                  rearrangement\n\n          -  Patients must have at least 1 of the following:\n\n               -  Severe neutropenia (absolute neutrophil count (ANC) less than 500/mm^3)\n\n               -  Neutropenia (ANC less than 1,000/mm^3) and recurrent infections\n\n               -  Anemia (hemoglobin less than 9 g/dL)\n\n               -  Thrombocytopenia (platelet count less than 50,000/mm^3)\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  NCI CTC 0-3\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  See Disease Characteristics\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2 times upper limit of normal (ULN)\n\n        Renal:\n\n          -  Creatinine no greater than 2 times ULN\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  No concurrent hormonal therapy except steroids for adrenal failure or hormones for\n             nondisease-related conditions (e.g., insulin for diabetes)\n\n          -  No concurrent dexamethasone or other steroidal antiemetics\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No prior cyclosporine therapy for this leukemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00031980", 
            "org_study_id": "CDR0000069246", 
            "secondary_id": "CALGB-10003"
        }, 
        "intervention": {
            "intervention_name": "cyclosporine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage I chronic lymphocytic leukemia", 
            "stage II chronic lymphocytic leukemia", 
            "stage III chronic lymphocytic leukemia", 
            "stage IV chronic lymphocytic leukemia", 
            "T-cell large granular lymphocyte leukemia", 
            "anemia", 
            "neutropenia", 
            "thrombocytopenia"
        ], 
        "lastchanged_date": "April 24, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CALGB-10003"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263-0001"
                }, 
                "name": "Roswell Park Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia", 
        "overall_official": {
            "affiliation": "University of Maryland Greenebaum Cancer Center", 
            "last_name": "Maria R. Baer, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Frequency of cytopemic response", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00031980"
        }, 
        "responsible_party": {
            "name_title": "Monica M. Bertagnolli", 
            "organization": "Cancer and Leukemia Group B"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Cancer and Leukemia Group B", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2008"
    }, 
    "geocoordinates": {
        "Roswell Park Cancer Institute": "42.886 -78.878"
    }
}